NewLimit Raises $130M to Advance AI-Driven Anti-Aging Therapies
NewLimit, a biotechnology startup focused on extending human healthspan by genetically reprogramming cells, has secured $130 million in a Series B funding round led by venture capital firm Kleiner Perkins. The raise marks a significant milestone for the four-year-old company as it accelerates efforts to develop breakthrough anti-aging therapies powered by artificial intelligence and cellular biology. The round attracted new investors including Nat Friedman, Daniel Gross, and Khosla Ventures, while previous backers such as Founders Fund, Dimension Capital, Elad Gil, Garry Tan, and Stripe co-founder Patrick Collison also recommitted to the vision. This latest infusion of capital follows a $40 million Series A round raised in 2022. Co-founded by Coinbase CEO Brian Armstrong, former GV (Google Ventures) partner Blake Byers, and stem cell researcher Jacob Kimmel, NewLimit is working to develop treatments that could rejuvenate aged cells, potentially delaying or reversing the effects of...